Barclays bullish on Globus Medical, sees share upside to $103

Barclays analyst Matt Miksic says that despite Globus Medical’s (GMED) Q1 miss, which was a surprise, it remains bullish on the shares. The firm continues to expect increased robotic surgery system sales, implant pull-through and new product launches to drive high-single-digit and potentially double-digit sales growth for both sides of the business in the second half of 2025 and beyond. Globus remains one of the analyst’s highest conviction recommendations. The stock is trading at a 40% discount and improving results in Q2 and the second half of the year should drive the shares toward Barclays’ $103 price target the analyst tells investors in a research note. The firm keeps an Overweight rating on the name.